

*This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.*

14 October 2020

**Kromek Group plc**  
(“Kromek” or the “Group”)

**Kromek's CZT-based detectors to be used to improve patient outcomes from cancer surgery**

*New R&D project with Adaptix Ltd and the University of Manchester to enhance pathological medical imaging techniques used during cancer surgery*

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, is pleased to announce that it has commenced development of a new system to improve the pathological medical imaging techniques used during cancer surgery to distinguish between healthy and non-healthy tissue – a new application area for Kromek's technology. The three-year project, which has received grant funding from Innovate UK, is being conducted in partnership with Adaptix Ltd, the developer of a Flat Panel X-ray Source (FPS), and the University of Manchester.

When a cancerous tumour is excised, the surgeon also removes some tissue around the edge of the tumour (the ‘margins’) to be sure that all the cancer has been removed and is not able to spread. These margins are checked for cancerous tissue while surgery is ongoing using ‘pathology cabinets’ that provide 2D or 3D images.

The project is to develop a prototype of a new type of pathology cabinet, based on Kromek's CZT detectors and Adaptix's FPS, to produce high-resolution 3D images that provide more accurate differentiation of the boundaries between diseased and healthy tissue. This will enable surgeons to confidently remove the minimum amount of healthy tissue whilst reducing the risk of more than one operation being needed and of cancer spreading from diseased tissue being left after initial surgery. The new system will also be designed to be cost effective and have a small footprint for ease of use in an operating theatre.

Kromek's CZT detectors are already incorporated into medical devices used for early detection of diseases such as breast cancer, cardiac conditions and osteoporosis.

Dr Arnab Basu, CEO of Kromek, said: “This is an exciting project for Kromek as it takes our CZT-based detectors into a new application area. Our technology is already being used by leading OEMs to enable the early diagnosis of cancer. With this system, we will contribute to improving the outcome of surgeries through greater image quality. It will reduce the risk of diseased tissue remaining and further surgeries being required while minimising the removal of healthy tissue, which will be of great benefit to both healthcare providers and patients. We look forward to working alongside our partners, Adaptix and the University of Manchester, to complete the development of this new system and take it to the next stage.”

**For further information, please contact:**

**Kromek Group plc**

Arnab Basu, CEO  
Derek Bulmer, CFO

+44 (0)1740 626 060

**Luther Pendragon (PR)**

Harry Chathli  
Claire Norbury  
Alexis Gore  
Joe Quinlan

+44 (0)20 7618 9100

**About Kromek Group plc**

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride (“CZT”) and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group’s products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group’s business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits (“ASICs”).

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over one hundred full-time employees across its global operations. Further information on Kromek Group is available at [www.kromek.com](http://www.kromek.com) and <https://twitter.com/kromekgroup>.